CSI is a clinical CRO that provides cost-effective clinical solutions through its team of experienced clinical research professionals and partners with broad knowledge of local clinical trial practices, requirements, and regulations
ClinChoice acquires CSI Medical Research. (Credit: Chokniti Khongchum from Pixabay)
US-based contract research organisation (CRO) ClinChoice has acquired Singapore-based CSI Medical Research (CSI) to expand its footprint in Southeast Asia.
CSI is a clinical CRO that provides advanced and cost-effective clinical solutions, with professional staff and partners located across Southeast Asia, Australia, and New Zealand.
The company has a team of experienced clinical research professionals with broad knowledge of local clinical trial practices, requirements, and regulations.
Through the acquisition, ClinChoice is enabled to further widen its global footprint and full-service capabilities in more than 30 countries throughout Asia, Europe, and North America.
CSI Medical Research founder and CEO Nelson Wong said: “We are excited to leverage on our familiarity with the SEA and ANZ regulations as well as the clinical sites within a region we called home, to assist more customers to navigate through the challenges with great speed and better cost efficiencies.
“CSI’s vision and mission in the approach to manage clinical trials are very much aligned with ClinChoice, and the company’s high-quality, efficiency and teamwork culture will be fantastic for our talented employees and clients alike. We are very looking forward to what we can achieve together.”
ClinChoice is engaged in providing full-service solutions across the entire lifecycle for pharmaceutical, biotechnology, medical device, and consumer product companies.
The company established deep regulatory know-how, clinical trial execution and data management capability across all major markets and regions around the world.
With more than 4,000 professionals worldwide, ClinChoice has completed more than 1,500 full-service clinical studies across all clinical trial phases and covering all major therapeutic areas.
ClinChoice Global chairman and CEO Ling Zhen said: “This is an exciting time for ClinChoice, and we are thrilled to welcome the talented CSI team to the ClinChoice family.
“With their wide range of highly valuable service offerings and seasoned professional team, the acquisition of CSI will further expand our presence in SEA and ANZ, and enhance our capability to well fulfil our clients’ needs locally and globally.”